Objective: To examine rates and predictors of receiving a psychosocial service before initiating antipsychotic treatment among young people in the Medicaid program.
T he use of antipsychotic medications for children and adolescents has increased sharply in the era of secondgeneration antipsychotics. [1] [2] [3] [4] Clinical trials support the efficacy of several antipsychotics for bipolar mania in children and adolescents, 5 schizophrenia in adolescents, 6 and irritability associated with autistic disorder in adolescents and children. 7 In practice, however, antipsychotics are often used for a wider range of disorders, including the management of disruptive behaviors and aggression in the context of attention-deficit/hyperactivity disorder 8 (ADHD) and disruptive, impulse-control, and conduct disorders. 9 In one study of 208 antipsychotic-treated children aged 2-15 years, the prescribing physicians indicated that the target symptoms were most commonly aggression (47%), behavioral difficulties (26%), and anxiety (17%), and less commonly hyperactivity (10%), mood disturbances (9%), psychotic symptoms (7%), and other symptoms. 10 In a recent national study of Medicaid-enrolled children, the use of antipsychotics increased 62% between 2002 and 2007; by 2007, ADHD was the leading diagnosis, representing 50% of children on antipsychotics. 11 Only about one-third (33%) of second-generation antipsychotic prescriptions to young people in the United States are for disorders for which there is at least good or moderate evidence of antipsychotic effectiveness. 12 In view of widespread antipsychotic medication prescription to young people for conditions without strong supporting clinical evidence, concerns have been raised over the effects of antipsychotic medications on their cardiovascular and metabolic health. 13, 14 Given the established health risks associated with antipsychotic medications, attention has also focused on strategies to minimize unnecessary antipsychotic treatment of children and adolescents. 15 An increased role for evidence-based psychosocial and behavioral interventions early in the course of treatment for children who present with externalizing problems has been suggested as one means of potentially reducing clinical treatment with antipsychotics for nonpsychotic disorders in young people. 16, 17 Externalizing symptoms are widely distributed across psychiatric disorders in clinical populations. 18 A substantial body of clinical research supports the efficacy of outpatient psychosocial treatments for disruptive behavior problems in children and adolescents. A meta-analysis of 32 controlled studies of children and adolescents reported moderate reductions in teacher-reported aggression and improved social function with stronger effects associated with behavior therapy than with family therapy, although the literature is better developed for children than for adolescents. 19 In children less than 8 years of age, a recent meta-analysis of 36 controlled trials further demonstrated large and sustained beneficial effects of parent-child interaction therapy, a positive parenting program, and other psychosocial treatments on disruptive behavior problems, with especially strong effects on externalizing problems and oppositionality. 20 Even in children with autism, a meta-analysis of 34 studies supports the effectiveness of early intensive behavioral interventions to improve adaptive and to reduce maladaptive behaviors. 21 The American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameter for the Use of Atypical Antipsychotic Medications in Children and Adolescents recommends that with the important exception of US Food and Drug Administration (FDA)-indicated conditions, clinicians should consider psychosocial or other pharmacological interventions with established safety and efficacy profiles before initiating an antipsychotic. 22 There are few data available on the overall extent to which youth receive psychosocial interventions before starting an antipsychotic medication. Prior research in this area has been limited to characterizing the proportion of young people receiving antipsychotics who also receive psychosocial treatments rather than the percentage who receive a psychosocial intervention before starting an antipsychotic medication. In a study of a mid-Atlantic state Medicaid-managed care plan, for example, 68% of youth 6 to 17 years of age who were starting treatment with an antipsychotic in 2006 to 2009 received combined medication management and psychotherapy. 23 Among very young privately insured children receiving an antipsychotic, the proportion receiving any psychotherapy decreased from 50% in 1999 to 2001 to 41.4% in 2007 . 24 This trend is consistent with a broader trend in US mental health service provision toward a declining percentage of treated individuals receiving psychotherapy, either alone or in combination with a psychotropic medication.
We assess patterns in access to psychosocial interventions before initiating treatment with an antipsychotic for children 0 to 20 years of age in 8 state Medicaid programs. Given concerns over access to psychosocial services, particularly for children and adolescents receiving antipsychotics who have ADHD or disruptive behavior disorders, we examine access to psychosocial services before antipsychotic initiation, stratified by patient characteristics and clinical diagnoses with and without FDA indications for antipsychotic use.
METHOD Study Design and Data Source
This was a retrospective cohort study using 2008 Medicaid Analytic eXtract (MAX) claims and managed care encounter data from 8 states (GA, IN, KS, KY, MI, MO, NM, and RI). States were selected based on their Medicaid data quality, including completeness of managed care enrollees in states using managed care. 25, 26 The study was approved or deemed exempt from review by the institutional review boards of New York State Psychiatric Institute, Rutgers University, and the National Committee for Quality Assurance.
Study Population
Medicaid-enrolled children and adolescents, 0 to 20 years of age, with a new start of an antipsychotic, were included in the study. A new start was defined as the first antipsychotic prescription in 2008 preceded by 120 days without any antipsychotic (see Table S1 , available online, for antipsychotics). Continuous enrollment criterion was 120 days before to 30 days after antipsychotic initiation. Medicare/Medicaid dually eligible youth were excluded. The unduplicated number of young persons meeting eligibility criteria was 24,372.
Definitions and Measures
Young people were grouped into 4 age categories: younger children (0-5 years), older children (6-12 years), younger adolescents (13-17 years), and older adolescents (18-20 years) . Race/ethnicity categories were white non-Hispanic, African American non-Hispanic, Hispanic, and other. Managed care status was categorized as any versus no managed care. County of residence was categorized as metropolitan, non-metropolitan urban, and rural, by merging MAX county of residence with the Area Resource File Rural-Urban Continuum Code (2003) . 27 Eligibility categories were foster care, income based, Supplemental Security Income, and other. Behavioral health hospital use was defined as any hospitalization with a behavioral health diagnosis during 2008.
Young people were assigned to 1 of 16 hierarchical diagnoses based on an examination of all diagnoses associated with any claim or encounter in 2008 (see Table S2 , available online). The hierarchical ordering is based on FDA indications and data on antipsychotic prescribing practices for young people to identify the diagnosis most likely to be the target for the antipsychotic treatment.
3,11 These 16 diagnostic groups (indicated in parentheses) were subsequently aggregated into 9 diagnostic categories, as follows: developmental and tic disorders (#1-2); psychotic or bipolar disorders (#3-5); disruptive behavior disorders (#6-8); ADHD (#9); stress disorders (posttraumatic stress disorder [PTSD] #10, and adjustment disorder #14); obsessive-compulsive disorder (OCD, #11); major depressive disorder (MDD, #12); anxiety disorder (#13); and substance use disorder or other mental health disorders (#15-16).
An outpatient psychosocial service prior to a new start of an antipsychotic was the outcome measure. Youth with 1 or more psychosocial services within 90 days before starting an antipsychotic medication were identified using Current Procedural Terminology (CPT) codes, including individual, group, and family psychotherapy, intensive outpatient, and other psychosocial interventions (see Table S3 , available online, for CPT codes used). We selected 90 days before antipsychotic initiation based in part on measure testing; extending the window to 120 days identified only 1.3% more additional children with psychosocial services.
Data Analysis
Analyses were performed using SAS, version 9.2 (SAS Institute, Cary, NC). Descriptive statistics were calculated for the cohort of young people with a new start of an antipsychotic. Prevalence of a psychosocial visit before a new start of an antipsychotic was calculated for children with 1 or more mental health diagnoses for each of the 16 diagnostic groups, 9 diagnostic categories, and all other covariates examined. Exact (Clopper-Pearson) confidence limits for the binomial distributions were reported, and logistic regression was used to estimate the independent bivariate and multivariate relationships. 28 Specifically, unadjusted odds ratios (ORs) were calculated with 95% CIs to determine the independent effects of each covariate on the likelihood of receiving psychosocial services before receiving an antipsychotic. A corresponding set of logistic regression models was fit for each stratum controlling for all other demographic, eligibility, hospitalization, and diagnostic characteristics. All tests of significance were 2-tailed. For diagnoses, the psychotic and bipolar diagnostic category (where first-line use of antipsychotic medications is appropriate) was used as the referent group for comparisons to other diagnostic categories.
RESULTS

Characteristics of Medicaid-Enrolled Youth With a New Start of Antipsychotics
A majority of Medicaid-enrolled children and adolescents, aged 0 to 20 years, with a new course of antipsychotic medications, were white, male, living in metropolitan areas, enrolled in a Medicaid-managed care plan, and had income-based eligibility (Table 1) . Approximately onefourth had a diagnosis of schizophrenia, depression with psychotic features, or bipolar disorder (BD) during the study year. Children and adolescents with disruptive behavioral disorders including oppositional, conduct, or impulse control disorders represented another quarter, and slightly less than one-fourth had ADHD without a higherlisted disorder (Table 1) . Together, young persons with disruptive behavioral disorders and ADHD, without comorbid psychotic, bipolar, or developmental disorders, comprised approximately one-half (46.4%) of the sample with a new start of an antipsychotic.
Socio-Demographic Determinants of Access to Psychosocial Services
Overall, less than one-half of the children and adolescents initiating antipsychotic treatment received a psychosocial service before starting the antipsychotic (48.85%) ( Table 2) . Oppositional (6) 14.09 Conduct (7) 8.08 Impulse control (8) 1.73 ADHD (9) 22.74 Stress disorders 3.17 PTSD (10) 1.60 Adjustment (14) 1.57 OCD (11) 0.23 Major depression (12) 5.72 Anxiety (13) 1 www.jaacap.org Among age categories, younger children and older adolescents were significantly less likely than younger adolescents to receive a psychosocial service before receiving an antipsychotic. Females were more likely than males to receive a psychosocial service. In non-metropolitan urban areas, young persons were less likely to receive psychosocial services before initiating antipsychotics than those in metropolitan areas. Young persons in foster care were significantly more likely to receive psychosocial services than those with income-related eligibility. Study patients enrolled in Medicaid-managed care were significantly less likely than those in fee-for-service settings to receive psychosocial treatment before antipsychotic medication.
Access to Psychosocial Services by Diagnostic Group
Diagnosis was an important predictor of receipt of psychosocial services before initiating antipsychotic treatment ( Table 2) . As compared with children and adolescents diagnosed with psychotic or BDs, those diagnosed with ADHD, depression, anxiety, and substance use were significantly less likely to receive a psychosocial service before being treated with an antipsychotic medication. In addition, children and adolescents diagnosed with pervasive developmental disorder and autism were also significantly less likely than those diagnosed with psychosis or BD to receive a psychosocial service before an antipsychotic medication. By contrast, young people diagnosed with stress disorders were significantly more likely than their counterparts diagnosed with psychotic or BDs to receive a psychosocial intervention before receiving an antipsychotic medication ( Table 2) .
DISCUSSION
In this 8-state sample of publicly insured children and adolescents, less than one-half received psychotherapy or behavioral interventions before initiation of antipsychotic treatment. Young persons diagnosed with ADHD, depression, anxiety disorders, and substance use disorders, all conditions without FDA-approved antipsychotic indications in youth, were significantly less likely to receive a trial of psychosocial services before antipsychotic treatment than corresponding youth with psychotic disorders or BD diagnoses. These findings suggest that antipsychotic medications are being used ahead of psychosocial services for many young people, especially for conditions without strong empirical support for antipsychotic efficacy. Potential risks of this service use pattern are underscored by the metabolic risks of antipsychotics in children and adolescents and uncertainties concerning the long-term safety of antipsychotic medications on the developing brain. 29 For many children and adolescents with ADHD and disruptive disorders, it is likely that aggression and disruptive behaviors are the clinical targets of antipsychotic treatment. Clinical practice guidelines addressing the management of aggression or disruptive disorders in children and adolescents recommend the use of psychosocial interventions before use of antipsychotics, 22, 30 including children with autism. 31 In the present study, children and adolescents with autism and pervasive developmental disorders or ADHD were less likely to receive a psychosocial intervention before receiving antipsychotics than were youth with psychotic or BD diagnoses. This pattern may reflect the relatively more intensive mental health service use pattern associated with childhood-or adolescent-onset BD and schizophrenia. However, the pattern of failure to receive psychosocial services before antipsychotic medication was prevalent across all diagnostic categories, ranging from 37% of cases in PTSD to 74% in substance abuse and other disorders.
Younger children were especially unlikely to have received psychosocial services before starting antipsychotic medications. Only around one-third (39%) of Medicaidfinanced young children received a psychosocial intervention in the 12 weeks before starting an antipsychotic medication. This pattern demonstrated widespread nonconformance with the American Academy of Child and Adolescent Psychiatry Preschool Psychopharmacology Working Group's recommendation for psychosocial interventions before initiating any psychotropic medication in www.jaacap.org a very young child. 32 One potential explanation is that pediatricians, who may have less access to psychosocial services, are proportionately more involved in the prescription of antipsychotics to younger rather than older children. 33 Inadequate numbers of professionals trained in evidencebased psychosocial interventions for children and adolescents, especially in rural areas, together with long waiting lists at specialized mental health clinics that serve Medicaid beneficiaries, may leave many front-line clinicians with few options other than antipsychotics for young persons who present with serious aggressive or disruptive behaviors.
Some subgroups were more likely to receive these psychosocial services than others, including children and adolescents in foster care as well as youth diagnosed with trauma and stress disorders, including PTSD and adjustment disorder. Previous reports have found that children in foster care are more likely to receive antipsychotic medications [34] [35] [36] [37] [38] than other Medicaid eligibility groups, but they are also more likely to receive services. 39 This study extends previous work by demonstrating that children and adolescents in foster care are more likely to have received psychosocial services before initiation of an antipsychotic. Nevertheless, given the stresses and trauma that these children have typically experienced, as well as the legal and ethical responsibilities of states to ensure appropriate care, the finding that 43% of foster care youth did not receive psychosocial services before antipsychotic initiation reveals an important opportunity for quality of care improvement. For children and adolescents with PTSD, for whom psychosocial interventions are the treatment of choice, and there is limited evidence to support the effectiveness of antipsychotics, 40 nearly two-thirds (62.6%) received at least one psychosocial intervention before initiation of an antipsychotic.
Children and adolescents enrolled in a Medicaidmanaged care plan were less likely than those in fee-forservice settings to receive a psychosocial intervention. Medicaid-managed care plans, which have grown rapidly in recent years, 41 have the authority to incentivize appropriate access to psychosocial services, and states that contract with them have the ability to monitor their performance with quality measures and to enforce quality and network adequacy standards in this area. More study is needed to examine the impact of increasing access to psychosocial services before antipsychotic initiation. We do not know what proportion of children and adolescents, if provided psychotherapy or other psychosocial interventions early in the course of treatment, would no longer be considered clinical candidates for an antipsychotic. A reduction in the use of antipsychotics may yield reduced pharmacy and medical costs associated with adverse effects of antipsychotics. [42] [43] [44] More research is needed to understand the complex array of factors that influence access and use of psychosocial treatments for children, and to identify strategies for improving access. Barriers to psychosocial services likely vary with treatment setting. Prior research has demonstrated that among Medicaid-financed children with ADHD, psychosocial services are far less commonly provided to children treated in primary care than in specialty mental health settings. 45 Co-located mental health services, when they are available, greatly facilitate mental health care referrals from primary care pediatricians. 46 When youth are referred by primary care physicians to outside mental health specialists, most of them do not keep their appointments. 47 In addition, many mental health practitioners have not been trained in evidence-based interventions for youth with disruptive behavioral problems. 48 To place the current treatment patterns in a broader context, it would be helpful to determine rates of psychosocial service use among Medicaid-financed young persons before starting other classes of psychotropic medications.
This study has several limitations. First, it is not possible to validate the diagnoses for the study population. Second, we used a hierarchical assignment of diagnoses that provides an opportunity to compare rates of psychosocial interventions across mutually exclusive diagnostic groups. However, different results would have been obtained had no hierarchy been imposed. Third, we did not examine psychosocial services that occurred more than 3 months before initiation of antipsychotic medications or the extent to which psychosocial services prevented the need to initiate antipsychotic medications. Fourth, we cannot observe any services used by health care professionals who were not paid by Medicaid, for example, psychosocial services in school, and we do not have information on the quality or type of psychosocial services delivered. Fifth, clinical considerations, especially in the management of severe psychiatric disorders, may necessitate initiating antipsychotic medications before psychosocial treatments. Moreover, consensus recommendations do not support psychosocial interventions before antipsychotic medications in conditions for which antipsychotic medications are FDA approved. Sixth, because Medicaid data do not include a measure of symptom severity, it was not possible to determine the extent to which psychosocial services preceding antipsychotic medication use varied by this key clinical dimension. Finally, the data were collected in 2008, and since that time, there may have been changes in the patterns of antipsychotic treatment of Medicaid-financed services or their use of psychosocial services.
The results of this study suggest that psychotherapy and behavioral interventions are not consistently used as first-line treatment options for Medicaid-financed youth before starting antipsychotic treatment. Although many children and adolescents receiving antipsychotics have diagnoses for which psychotherapy is a first-line treatment, only a minority receive psychosocial services before initiating antipsychotic medications. High rates of antipsychotic use in youth with such disorders suggest that the severity of these behaviors is often considered substantial and that there is a pressing need to increase the availability of psychosocial interventions, particularly evidence-based interventions. Striking a balance between ensuring appropriate access to antipsychotics as needed while reinforcing and incentivizing access to evidence-based psychosocial interventions represents a key quality challenge for public mental health. & 
